# Post Authorization Efficacy and Safety Study (PAES) to Confirm and Collect More Clinical Data of Buccalin® Tablets In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIs).

> **NCT06736288** · PHASE4 · RECRUITING · sponsor: **Laboratorio Farmaceutico SIT srl** · enrollment: 240 (estimated)

## Conditions studied

- Respiratory Infection
- Lower Respiratory Tract Infection (LRTI)

## Interventions

- **DRUG:** BUCCALIN®
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06736288
- **Lead sponsor:** Laboratorio Farmaceutico SIT srl
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-21
- **Primary completion:** 2027-04
- **Final completion:** 2029-04
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06736288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06736288, "Post Authorization Efficacy and Safety Study (PAES) to Confirm and Collect More Clinical Data of Buccalin® Tablets In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIs).". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06736288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*